Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Soleus Capital Management L.P.

Soleus Capital Management L.P. grew its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 97.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,102,833 shares of the company's stock after buying an additional 1,036,999 shares during the period. Nurix Therapeutics accounts for 2.5% of Soleus Capital Management L.P.'s investment portfolio, making the stock its 12th largest holding. Soleus Capital Management L.P. owned about 2.77% of Nurix Therapeutics worth $39,617,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of NRIX. US Bancorp DE boosted its holdings in shares of Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after buying an additional 842 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Nurix Therapeutics in the 4th quarter valued at $87,000. Summit Investment Advisors Inc. boosted its holdings in shares of Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after buying an additional 877 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Nurix Therapeutics in the 4th quarter valued at $164,000. Finally, Nomura Holdings Inc. acquired a new position in shares of Nurix Therapeutics in the 4th quarter valued at $198,000.

Analyst Ratings Changes

A number of brokerages recently weighed in on NRIX. Royal Bank of Canada increased their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 29th. Wall Street Zen cut shares of Nurix Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday. Needham & Company LLC reiterated a "buy" rating and set a $27.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $30.44.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the transaction, the insider now directly owns 61,516 shares in the company, valued at approximately $707,434. This trade represents a 5.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the sale, the chief financial officer now owns 33,724 shares of the company's stock, valued at approximately $488,660.76. This trade represents a 14.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 17,838 shares of company stock worth $221,500. 7.40% of the stock is owned by corporate insiders.

Nurix Therapeutics Trading Down 2.7%

Shares of NRIX traded down $0.27 during trading hours on Friday, reaching $9.72. The company had a trading volume of 401,505 shares, compared to its average volume of 871,857. The firm has a 50 day simple moving average of $10.67 and a 200-day simple moving average of $16.39. The company has a market capitalization of $741.01 million, a price-to-earnings ratio of -3.36 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The firm had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. During the same period last year, the firm posted ($0.76) EPS. Sell-side analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.